BioTissue, Inc.

BioTissue is a pioneering biotechnology company and recognized leader in regenerative medicine, specializing in innovative applications of human birth tissues for wound healing and ocular health. Founded in 1997, the company has spent over four decades advancing the science of amniotic membrane technology, developing proprietary products derived from human placental tissues that promote regenerative healing. With more than 1.2 million human clinical applications performed and over 440 peer-reviewed publications documenting their groundbreaking work, BioTissue has established itself as the trusted standard in ocular surface disease treatment.

The company's flagship products include Prokera, AmnioGraft, AmnioGuard, and CAM360 AmnioGraft, which utilize the proprietary CryoTek cryopreservation technology designed to retain the tissue's structural and functional integrity. BioTissue's cryopreserved amniotic membrane (CAM) is the only amniotic membrane recognized by the FDA for anti-inflammation, anti-scarring, and anti-angiogenesis. Eye care professionals use these products to treat conditions including Neurotrophic Keratitis, Persistent Epithelial Defects, and various ocular surface diseases. Headquartered in Miami, Florida, BioTissue continues to pursue FDA approval through Biologics License Applications while expanding its impact across the regenerative medicine landscape.